{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:52:42Z","timestamp":1791870762018,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejca.2021.12.009","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T06:16:47Z","timestamp":1641363407000},"page":"148-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["UGT1A1 genotype-guided dosing of irinotecan: A\u00a0prospective safety and cost analysis in poor metaboliser patients"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-6253","authenticated-orcid":false,"given":"Emma C.","family":"Hulshof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-7945","authenticated-orcid":false,"given":"Mirjam","family":"de With","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke M.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-1996","authenticated-orcid":false,"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit A.L.M.","family":"Deiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8680-1380","authenticated-orcid":false,"given":"Saskia","family":"Houterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8280-9836","authenticated-orcid":false,"given":"Sander","family":"Bins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.J.","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan M.J.","family":"Laven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke M.","family":"H\u00f6vels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-2878","authenticated-orcid":false,"given":"Saskia A.C.","family":"Luelmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Houtsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9004-9232","authenticated-orcid":false,"given":"Howard L.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-6420","authenticated-orcid":false,"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.12.009_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","volume":"57","author":"de Man","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2021.12.009_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2021.12.009_bib3","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2008.21.2480","article-title":"Irinogenetics: how many stars are there in the sky?","volume":"27","author":"Mathijssen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2015.23","article-title":"Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study","volume":"16","author":"Crona","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ejca.2021.12.009_bib5","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","article-title":"Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics","volume":"27","author":"Innocenti","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib6","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2021.12.009_bib7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in gilbert's syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.12.009_bib8","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","article-title":"Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients","volume":"10","author":"Rouits","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.009_bib9","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1349-7006.2011.02030.x","article-title":"Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1\u221728 and\/or UGT1A1\u22176 polymorphisms","volume":"102","author":"Satoh","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2021.12.009_bib10","first-page":"1","article-title":"Life-threatening irinotecan-induced toxicity in an adult patient with alveolar rhabdomyosarcoma: the role of a UGT1A1 polymorphism","volume":"2017","author":"Jannin","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.ejca.2021.12.009_bib11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","article-title":"UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer","volume":"91","author":"Marcuello","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cncr.21722","article-title":"Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy","volume":"106","author":"Massacesi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib13","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1\u221728 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.12.009_bib15","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1158\/1078-0432.CCR-10-1122","article-title":"Dose-dependent association between UGT1A1\u221728 genotype and irinotecan-induced neutropenia: low doses also increase risk","volume":"16","author":"Hu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.12.009_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/tpj.2013.10","article-title":"Association of UGT1A1\u221728 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians","volume":"14","author":"Liu","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ejca.2021.12.009_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.7150\/jca.17210","article-title":"Predictive value of UGT1A1\u221728 polymorphism in irinotecan-based chemotherapy","volume":"8","author":"Liu","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib18","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ejca.2010.02.049","article-title":"Dose-dependent association between UGT1A1\u221728 polymorphism and irinotecan-induced diarrhoea: a meta-analysis","volume":"46","author":"Hu","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cpt.1049","article-title":"Pharmacogenetic information in clinical guidelines: the European perspective","volume":"103","author":"Swen","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2021.12.009_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bjc.2011.206","article-title":"A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil\/leucovorin as first-line treatment in advanced colorectal cancer","volume":"105","author":"Marcuello","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10637-013-0034-9","article-title":"UGT1A1 genotype-guided phase i study of irinotecan, oxaliplatin, and capecitabine","volume":"31","author":"Goetz","year":"2013","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.ejca.2021.12.009_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-009-1008-7","article-title":"Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors","volume":"65","author":"Denlinger","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2021.12.009_bib23","doi-asserted-by":"crossref","unstructured":"NCI. Common Terminology Criteria for Adverse Events. n.d. https:\/\/doi.org\/10.32388\/erjxiq.","DOI":"10.32388\/ERJXIQ"},{"key":"10.1016\/j.ejca.2021.12.009_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6600447","article-title":"Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38","volume":"87","author":"Mathijssen","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2000.18.1.195","article-title":"Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose- escalating study of irinotecan and cisplatin","volume":"18","author":"De Jonge","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib26","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/cncr.25735","article-title":"Clinical implications of UGT1A1\u221728 genotype testing in colorectal cancer patients","volume":"117","author":"Shulman","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib27","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjc.6604461","article-title":"UGT1A1\u221728 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study","volume":"99","author":"Kweekel","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib29","first-page":"97","article-title":"Utility of pretreatment bilirubin level and UGT1A1 polymorphisms in multivariate predictive models of neutropenia associated with irinotecan treatment in previously untreated patients with colorectal cancer","volume":"1","author":"Parodi","year":"2008","journal-title":"ADI"},{"key":"10.1016\/j.ejca.2021.12.009_bib30","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","article-title":"The role of UGT1A1\u221728 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer","volume":"24","author":"Toffoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib31","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2008.21.6283","article-title":"Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial","volume":"27","author":"Braun","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/cpt.615","article-title":"Cost evaluation of irinotecan-related toxicities associated with the UGT1A1\u221728 patient genotype","volume":"102","author":"Roncato","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2021.12.009_bib33","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1002\/cncr.24428","article-title":"Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer","volume":"115","author":"Gold","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/14622416.9.5.539","article-title":"Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer","volume":"9","author":"Obradovic","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejca.2021.12.009_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/0284186X.2015.1053983","article-title":"The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance","volume":"55","author":"Butzke","year":"2016","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.ejca.2021.12.009_bib36","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2014.55.2307","article-title":"Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer","volume":"32","author":"Innocenti","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.seminoncol.2017.02.007","article-title":"A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification","volume":"44","author":"Boisdron-Celle","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41416-018-0348-7","article-title":"Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype","volume":"120","author":"P\u00e1ez","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2021.12.009_bib39","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/JCO.2009.23.6125","article-title":"Genotype-driven phase I study of irinotecan administered in combination with fluorouracil\/leucovorin in patients with metastatic colorectal cancer","volume":"28","author":"Toffoli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.009_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.09.007","article-title":"Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time","volume":"141","author":"Hulshof","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:33Z","timestamp":1760733333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"alternative-id":["S0959804921012648"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UGT1A1 genotype-guided dosing of irinotecan: A\u00a0prospective safety and cost analysis in poor metaboliser patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}